Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials

Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials

Neurotoxicity is an off-tumour, on-target side effect of GD2-directed immunotherapy with monoclonal antibodies. Here, we report the frequency, management and outcome of patients enrolled in two prospective clinical trials who experienced severe neurotoxicity during immunotherapy with the anti-GD2 an...

Full description

Bibliographic Details
Main Authors: Aleksandra Wieczorek, Carla Manzitti, Alberto Garaventa, Juliet Gray, Vassilios Papadakis, Dominique Valteau-Couanet, Katarzyna Zachwieja, Ulrike Poetschger, Ingrid Pribill, Stefan Fiedler, Ruth Ladenstein, Holger N. Lode
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Cancers
Subjects:
neuroblastoma
anti-GD2 antibody
dinutuximab beta
neurotoxicity
Online Access:https://www.mdpi.com/2072-6694/14/8/1919

Internet

https://www.mdpi.com/2072-6694/14/8/1919

Similar Items